Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial

被引：0
|
作者：
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzmann, R.
Tinbergen, J.
Hauser, S. L.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Toronto, ON, Canada
[5] McGill Univ, Montreal, PQ, Canada
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P462
引用
收藏
页码：S194 / S195
页数：2
相关论文
共 50 条
  • [41] MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
    Francis, G
    Evans, A
    Panitch, H
    ANNALS OF NEUROLOGY, 1997, 42 (03) : T289 - T289
  • [42] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [43] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [44] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [45] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
  • [46] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Havrdova, E.
    Phillips, J. T.
    Fox, R. J.
    Miller, D.
    Kita, M.
    Hutchinson, M.
    Raghupathi, K.
    Yuan, H.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
  • [47] Real world experience with ocrelizumab in patiens with relapsing-remitting multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 301
  • [48] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [49] Ocrelizumab Alters the Circulating Metabolome in People with Relapsing-remitting Multiple Sclerosis
    Siavoshi, Fatemeh
    Ladakis, Dimitrios C.
    Muller, Ashley
    Nourbakhsh, Bardia
    Bhargava, Pavan
    ANNALS OF NEUROLOGY, 2024, 96 : S92 - S93
  • [50] Magnetic Resonance Imaging (MRI) Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis - Results of a Phase II Study
    Sorensen, Per
    Drulovic, Jelena
    Havrdova, Eva
    Lisby, Steen
    Derosier, Frederick
    Shackelford, Steve
    Filippi, Massimo
    NEUROLOGY, 2011, 76 (09) : A85 - A85
12345